Growth factor signaling plays a key role in the growth and development of breast. Aberrant expression and activation of growth factors like insulin like growth factor-I (IGF-I) and epidermal growth factor (EGF) and their downstream signaling has been implicated in breast cancer. The deregulation of growth factor signaling is associated with increased proliferation and cell survival, decreased apoptosis, invasion, angiogenesis and metastasis. The aim of the present study is to survey the different signaling molecules involved in the IGF and EGF signaling pathways, and to find if there are any relationship between breast cancer and their levels and activation. Thirty-nine samples of breast cancer tissues (24 Grade II and 15 Grade III tumours) and sixteen normal breast tissue samples were collected. The expression of the receptors and signaling molecules were investigated using Western blot. IGF-IRβ, AR, pAkt, IKK-α and p38 are upregulated in cancer tissues in a grade depended manner. Further, Akt and β-catenin were also upregulated in cancer samples. Correlation analysis of signaling molecules revealed a disruption in their expression in cancer tissues. The present study shows that various signaling molecules are upregulated or activated in cancer tissues involving IGF-IR and Akt pathway. The expression of signaling molecules in the cancer tissues were deregulated when compared to the control samples. Thus, flawed expression and over activation of Akt pathway is seen in the breast cancer tissues.
Introduction
Breast cancer is a worldwide health concern for women. Growth factors stimulate cellular growth, proliferation and differentiation and are vital for the normal development and function of the breast [1] . In breast cancer, insulin-like growth factor (IGF) and epidermal growth factor (EGF) signaling systems are affected leading to abnormal mitogenicity and cell survival. Further, estrogen act synergistically with growth factors to enhance the mitogenic effect of growth factors by inducing expression of several members of the IGF and EGF family [2] .
IGF signaling system plays a critical role in the growth and development of many tissues. However, IGF system is also implicated in various pathophysiological conditions and is thought to play a prominent role in tumorigenesis [3] . High serum IGF-I levels predict an increased risk of breast cancer [4] . Both experimental and clinical studies have demonstrated that IGF-IR is overexpressed in cancer cells compared with normal tissues [5] . EGF receptor (EGFR) has been considered a nodal point which converges many cytokine and hormone-induced signals to lead to MAPK activation [6] . EGFR signaling can induce epithelial to mesenchymal transition, invasion, and metastasis in different cancer cell types, including human breast cancer cells [7] .
Downstream signaling of growth factors involves Akt and ERK pathways which consist of an array of signaling molecules. Akt signaling pathway regulates diverse biological functions, including cellular proliferation, survival, and motility in cancer cells. Glycogen synthase kinase 3β (GSK-3β), a downstream molecule of Akt, is a key target of PI 3-kinase signaling leading to prevention of apoptosis [8] . β-catenin was a poor prognostic marker in human cancer and was implicated in human breast cancer. There is a strong correlation between β-catenin activity and cyclin D1 expression in both breast cancer cell lines and breast patient tissue samples and it also known to activate MMP-7 during cancer [9] . ERK is largely activated by growth factor signals [10] . Elevated MAPK activation was found in breast carcinoma compared with benign breast tissue [11] . The p38 MAPKs have also been shown to play roles in cell proliferation and survival. p38 MAPK also plays a role in the downstream signaling of VEGF leading to angiogenesis [12] . NF-κB has also been shown to be involved in the development of carcinomas, cancers of epithelial origin, such as breast cancer. The activation of NF-κB is controlled by IKK-α and IKK-β, by canonical pathway, NF-κB plays a major role in inflammation, cell survival, transformation, and oncogenesis in breast cancer [13] .
Breast cells are also under steroid hormone regulation with estrogen and progesterone controlling the rate of mitosis [14] . Estrogen receptors (ERs) belong to the ligand regulated transcription factors that transduce hormone signals into a large variety of physiological responses in various organs including breast. Both the genomic and non-genomic actions of estrogen play pivotal roles in E2-induced cancer cell proliferation and survival [15] . The role of the androgen receptor (AR) in breast carcinomas has drawn great attention in recent years, especially due to its expression in ER and PR negative breast carcinomas [16] . Epidemiologic studies showed that increased serum androgen level was associated with an increased risk for breast cancer in postmenopausal patients [17] . Hanley et al. investigated the potential role of AR in relation to breast tumor progression and showed that 93% of 43 high-grade ductal carcinoma in situ cases expressed AR, whereas only 55% of 44 high grade invasive ductal carcinomas showed AR expression showing a grade dependent upregulation [18] .
Thus several growth factor pathways and steroid receptors play various roles in cancer progression. Our objective for this study was is to survey the protein levels of the signaling molecules involved in the IGF and EGF signaling pathways along with ER and AR, and to find if there are any relationship between the breast cancer and the levels and activation of key signaling molecules.
Materials and Methods

Tissue Samples
The study was performed with approval of the 
Western Blotting
For protein extraction, 50 mg of tissue samples were lysed in pre-cooled RIPA-buffer containing phosphatase inhibitors (Pierce Biotechnology Inc, USA), proteinase inhibitors (Roche, Germany). Equal amount of total protein (35 μg) was mixed with 2X sample buffer and boiled for 5 min. The protein was separated on 10% SDS-PAGE and electrotransfered onto a PVDF membrane (Bio-Rad, USA). To avoid non-specific binding, membranes were blocked with 5% non-fat milk protein in PBS/Tween at RT for 3 hours. After blocking, membranes were incubated with respective rabbit polyclonal antibodies (Cell signaling Technologies, USA) pAkt (#9271S), Akt (#4685), pERk (#1972), Erk (#9102), pGSK (#9336), GSK (#9315), IKK-α (#2682), IKK-β (#2684), β-catanin (#9562), p38 (#9212), IGF-IRβ (#3027), EGRF (#4267), ERα (sc-543), and AR (sc-815), in 1:2000 dilution for overnight at 4˚C. For mouse monoclonal β-actin antibody in 1:5000 dilutions. Finally, signals were visualized using Enhanced Chemiluminescent System (Pierce Biotechnology Inc., USA) and the signals were captured by Chemi Doc XRS system (Bio Rad, USA) and the intensity of the bands were quantified by Quantity One software (Bio Rad, USA).
Data Analysis and Statistics
Protein expression data from normal (control) and cancer tissues were analysed by Kruskal-Wallis test followed by Mann-Whitney test. Protein expression data was further subjected to Pearson correlation analysis to identify the correlations between the signaling molecules within the control and within the cancer samples respectively. Correlation analysis for cancer samples were performed by pooling data from Grade II and Grade III. To analyse if there are any differences in the correlation coefficients between control and cancer tissues Fisher transformation analysis was performed for correlation coefficients with r > 0.8. SPSS 17.0 software package was used for data analysis and Graph Pad prism 5.0 software was used to draw graphs. Fisher transformation analysis was done using MedCalc software. Data was considered statistically significant when p < 0.05.
Results
Patients Data
In the present study, we analysed 24 Grade II samples and 15 Grade III samples from patients of age range from 29 to 85 with a mean age of 56 years. The patient data is summarized in Table 1 . The patients with Grade II tumour had bigger tumour size and the nodal status had no difference between the groups. More patients in Grade III tumour had lymph node metastasis at the time of diagnosis. The distribution of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) statuses is shown in Figures  1(a) and (b) . The ER, PR and HER2 status was done by immunohistochemistry.
IGF-IRβ and EGF-R Levels in Control and
Breast Cancer Samples IGF-IRβ is highly expressed in cancer and its protein level increased in Grade II (p < 0.001) and Grade III (p < 0.0001) when compared to control. There was no difference in the IGF-IRβ levels between Grade II and Grade III cancer samples (Figures 2 and 3(a) ). Our data also show that IGF-IRβ levels where upregulated in 87.2% of the cancer samples ( and 3(b) ). However, it is interesting to note that 59% of the cancer patients had elevated levels of EGF-R when compared to the controls ( Table 2 ) and 80% of Grade III patients have elevated levels of EGF-R (Table 2).
Expression of Signaling Molecules Downstream to IGF and EGF
The Akt protein level increased in Grade II (p < 0.003) when compared with control whereas pAkt levels showed increase in Grade III (p < 0.001) when compared to the control and showed a grade dependent increasing tendency (Figures 2, 3(c) and (d)). Akt and pAkt levels were more than the control levels in 71.8% and 69.2 % of the cancer patients respectively ( Table 2) . Neither ERK nor its phosphorylation levels show any difference between the control and the cancer tissue (Figures 2, 3 (e) and (f)). Similar observations were seen in the levels of GSK and pGSK (Figures 2, 3(g) and (h) ). IKK-α levels increased in cancer Grade II (p < 0.01) and Grade III (p < 0.001) when compared to controls showing a grade dependent increase with 87.2% ( 3(i) ). However, IKK-β did not display any changes (Figures 2 and 3(g), (j) ). The levels of p38 protein was higher in Grade II (p < 0.013) and in Grade III (p < 0.001) when compared with control ( Figures 2 and 3(k) ) with 79.5% of the cancer samples showing upregulation (Table 2). β-catenin also showed similar pattern with higher protein levels in Grade II (p < 0.031) and Grade III (p < 0.053) when compared to controls (Figures 2  and 3(l) ). Further, 84.6% of the cancer samples displayed upregulation when compared to the control samples ( Table 2) .
ERα and AR in Different Stages of Breast Cancer
The ERα expression did not show any difference between control and cancer tissues but showed an upregulating tendency (Figures 2 and 4(a) ). In 84.6% of the samples ERα expression was higher than the control samples ( Table 2) . AR expression progressively increased in Grade II (p < 0.002) and in Grade III (p < 0.0001) when compared with control ( Figures 2 and 4(b) ). It is interesting to note that AR levels were upregulated 84.6% of cancer samples when compared to the controls ( Table 2) .
Correlation between Signaling Molecules in Control and Cancer Tissues
Pearson correlation analysis was performed to find inter-relationship of the signaling molecules/receptors in control samples and to identify if this relationship is altered in cancer tissues. Results clearly indicate that correlation exists between the levels of various signaling molecules in the control samples ( Table 3) . There is a strong positive (r > 0.8) correlation between the levels of pERK and IKK-β (p < 0.001, r = (Table 4) . Further, comparison of corresponding correlation coefficients between control and cancer samples reveal that almost all except the correlations seen between IKKα vs. ERα, and β-catenin vs. IGF-IR in the control samples are lost in the cancer tissues ( Table 5 ).
Discussion
Growth factor signaling plays a vital role in the cancer progression cellular proliferation and metastasis. Substantial evidences implicate IGF signaling in the development and progression of many cancers, including breast cancer [19] and upregulation of IGF-I is often associated with poor prognosis [4] . The present study shows a grade dependent upregulation of IGF-IR in cancer tissues. Similar IGF-IR upregulation in cancer tissues were previously reported in Canadian population. Further, correlation analysis within the control and cancer samples show that in normal breast tissues IGF-IR has a positive correlation with GSK, β-catenin and ERα, but the correlation between IGF-IR and GSK, and IGF-IR and ERα was lost in cancer tissues indicating a perturbed expression of signaling molecules in cancer cells. Over expression of EGF-R in breast cancer is associated with large tumor size, poor differentiation and poor clinical outcomes. Further, EGF-R over expression has been associated with higher grade and extensive forms of ductal carcinoma in situ [20] . Although in the present study EGF-R did not increase in cancer tissues, it is important to note that its levels were upregulated in 80% of the Grade III patients. Similar upregulation of EGF-R inhigher grade cancer was has been reported [20] . Correlation analysis shows that in control samples EGF-R is positively correlated with pGSK, IKK-α, β-catenin, ERα and IGF-R, but in cancer tissues EGF-R lost all these correlations suggesting abnormal expression of these molecules which could lead to flawed signaling.
Our study also shows that the expressions of various downstream signaling molecules to the growth factor receptors are affected in cancer tissues. Akt pathway is an important regulator of cell proliferation and survival and is deregulated in breast cancer. In the present study pAkt shows a grade depended increase in cancer, suggesting hyper-activation of Akt molecules in cancer tissues. However, ERK expression and its phosphorylation did not show any increase in cancer tissues and pERK was lower in 67.6% cancer samples when compared to controls. Thus our data shows an apparent domination of Akt pathway over ERK pathway in cancer tissues. Western blot data shows that downstream signaling molecules of Akt are upregulated in cancer samples. IKK-α is a regulatory molecule of NF-κB, pAkt activates the IKK-α by phosphorylating it, and thereby activating the NF-κB [21] . Our data shows that there is an upregulation in the overall IKK-α expression and is increased in 87.2% of the cancer samples indicating an Akt induced IKK-α activation. Activated IKK-α could promote NF-κB mediated transcription [22] . GSK, a downstream signaling molecule of Akt did not show any change in its expression or phosphorylation. GSK is deactivated by phosphorylation [23] . The absence of increase in pGSK suggests that GSK is active even though its levels did not change. However, β-catenin which is downstream to GSK is highly expressed in cancer samples. β-catenin increases proliferation in ER positive breast cancer cells by activating cyclin D1 ( [9] . A previous study shows that higher expression of β-catenin along with p53 is correlated with worse survival [24] . Thus, signaling molecules downstream to Akt are highly expressed and activated in breast cancer tissues indicating abnormal activation of this pathway.
The role of p38 MAP kinase in cancer has been thought to occur through negative regulation of the cell cycle and senescence, suggesting that p38 MAPK is a tumor suppressor gene [25] . However, a recent study in MCF-7 breast cancer cell line shows that EGF-R phosphorylation leads to the activation of p38 mediated cell survival [26] . Previous study suggests that p38 activity was found to be upregulated in various carcinomas including that of the breast [27] . In the present study p38 is highly expressed in cancer tissue when compared with control indicating its role in breast cancer.
ER is often overexpressed in majority of in breast cancer along with IGF-IR. In this study, although ERα levels were not significantly upregulated, it was elevated in 84.6% of the samples when compared with normal tissues. Previous study shows that ERα binds in an estrogen depended manner to the p85α subunit of the PI3K, leading to the activation of Akt [28] . It is likely that in the ER positive patients Akt is activated via ERα but additional evidences are needed to confirm this possibility. Interestingly, AR was upregulated in a grade dependent manner with 75% of grade II and all of grade III samples showing upregulation.
AR upregulation has been shown in several earlier studies [18] . The upregulated AR expression may activate the p21 [29] , which is a positive regulator of cell cycle. Previous study also suggests that p21 overexpression is associated with tumor metastasis in canine mammary tumours [30] . By this mechanism AR can insert the no genomic action through this pathway.
Conclusion
In conclusion, the present study shows that several signaling molecules are upregulated/activated in cancer tissues in a grade depended manner, and the pathway involving IGF-IR and Akt seems to be actively involved in breast cancer tissues. Signaling pathways important for cell survival involving Akt are highly activated in cancer samples. Further, there is a deregulation in the expression of signaling molecules in the cancer tissues when compared to the control samples.
